Hyper-CVAD plus ponatinib versus hyper-CVAD plus dasatinib as frontline therapy for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: A propensity score analysis
scientific article published in August 2016
Author/s
author: Nicholas J. Short, Hagop Kantarjian, Farhad Ravandi, Guillermo Garcia-Manero, Jorge Eduardo Cortes, Naveen Pemmaraju, Tapan M Kadia, Marina Konopleva, Elias Jabbour, Koji Sasaki, Rebecca S Garris, Naval Daver, Ghayas C Issa, Susan O'Brien
Work details
Copyright status
Copyright status information is not available for this work. The copyright status depends on the jurisdiction, the author's date of death and the date the work was created or published.
To learn more about copyright terms in different countries, visit the countries and terms page.